Dr. Robert E. Bristow, MD

Dr. Bristow practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Bristow's NPI, 1427016039, was assigned on May 3, 2006. Dr. Bristow graduated from Keck School of Medicine of USC in 1991. Dr. Bristow holds California license G81369.

Dr. Bristow's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Bristow's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. Dr. Bristow is also affiliated with Long Beach Medical Center. The medical group on file is OB/GYN University Associates.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bristow practices, 2 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Bristow's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Bristow is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dmand AI has Dr. Bristow's licenses on file in 2 states: California and Maryland.

Dmand AI lists hysterectomy and ovarian cyst among the conditions Dr. Bristow treats.

CMS data shows 189 Medicare services from Dr. Bristow across 4 procedure codes in 2024, for 83 Medicare patients. Medicare paid $19,861 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 83 Medicare patients who saw Dr. Bristow in 2024. The largest group is 65 to 74, with 48 patients. 72% of them have high cholesterol, and 71% have high blood pressure. 36% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bristow's median patient age at 59, with 99% women.

In 2024, Dr. Bristow wrote 61 Medicare Part D claims for 28 patients. 66% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $125,975 in total drug cost. In 2023, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Bristow for performance year 2024, reported through an alternative payment model (APM). Dr. Bristow accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bristow as offering telehealth. CMS counts 13 procedures of removal of the uterus by Dr. Bristow, more than 87% of the clinicians it reports for that procedure.

Dmand AI links 236 papers to Dr. Bristow, published from 2005 to 2025. 2016 was the busiest year, with 6. The most frequent topics are Ovarian Neoplasms, Carcinoma, Ovarian Epithelial and Gynecologic Surgical Procedures. Dr. Bristow has published most often in Gynecol Oncol. Dr. Bristow's most frequent co-authors are Deborah K. Armstrong, MD, Dennis S. Chi, MD and William A. Cliby, MD.

Dmand AI links Dr. Bristow to 8 clinical trials, 5 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Adenocarcinoma, Clear Cell, Brenner Tumor and Fallopian Tube Diseases. Gynecologic Oncology Group sponsors the most, 4.

CMS Open Payments shows 7 general payments to Dr. Bristow from 5 drug and device companies from 2023 to 2025. Food and beverage make up the largest share, 100% of the total. Dilon Technologies, Inc. paid the most, $84.

Dmand AI lists 8 awards for Dr. Bristow, most recently America's Top Doctors in 2014.

Dr. Bristow graduated from Keck School of Medicine of USC in 1991. Dr. Bristow is a member of American College of Obstetricians and Gynecologists and ACS.

Dr. Bristow is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.